The Cancer Letter

Inside information on cancer research and drug development

In Brief

MUSC Hollings head and neck team awarded $3.5M to reduce delays in care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A multidisciplinary team at MUSC Hollings Cancer Center, led by Evan Graboyes, was awarded a $3.5 million grant to test an approach for reducing delays in care for head and neck cancer patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer. 
In Brief

Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings

Shikhar Mehrotra, professor of surgery and Cecilia and Vincent Peng Endowed Chair in melanoma and cutaneous oncology, will take on the role of co-leader of the Cancer Biology and Immunology Research Program at MUSC Hollings Cancer Center, alongside Philip Howe, professor and chair of the Department of Biochemistry & Molecular Biology, and Sophie Paczesny, professor in the Department of Microbiology & Immunology.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account